



Renal cell carcinoma (RCC) is a malignant kidney cancer involving
vascular solid tumours. One method of treatment uses anti-angiogenic
drugs (e.g. Sunitinib), which inhibit the growth of blood vessels to
starve the tumour cells. Although many patients initially respond to
these drug therapies, the tumours inevitably develop resistance. We
hypothesize that this adaptation involves a switch to a symbiotic
metabolism that allows continued survival and proliferation even in
conditions of low blood supply. Understanding the processes behind this
tumour resistance allows for treatments to be optimized to prevent
resistance while minimizing blood supply to the tumour.
This project aims to investigate the symbiotic metabolic response in
RCC to anti-angiogenic drug treatment. The objectives here are to
model the treatment naïve and symbiotic metabolisms present in the
cancer cells. The correctness of the model will be evaluated using stains





Based on the observations of [1], a model for the symbiotic metabolism
was constructed (Figure 1). It was hypothesized that lactate (produced
by anaerobic respiration, especially in low oxygen) was recycled into
pyruvate rather than being excreted, in order to provide additional fuel
for the tumour. As a result, lactate exporters (MCT4; normally in all
cells) were thought to be exclusively expressed far from blood vessels,
where oxygen is low. Correspondingly, lactate importers were thought
to be expressed near blood vessels (normally aren’t expressed at all).
To implement the models, an explicit finite difference scheme was used
to approximate the partial differential equation for diffusion (of oxygen,
glucose, and lactate) in MATLAB. Blood vessel locations from
histological stains by [1] were used as input (Figure 2). Pixels were
treated as cells, with vessels as constant glucose and oxygen sources.
Neumann “no-flux” boundary conditions were used along the stains’
borders to emulate mirrored vessel locations in the surrounding regions.
a) b)
Distributions of oxygen, glucose, lactate, and pyruvate at steady state
were then produced from the MATLAB simulation. The expected
lactate exporter (MCT4) distribution was predicted, and qualitatively
compared to the MCT4 distribution from histological stains in order to
test the accuracy of the model. Finally, the energy (ATP) production rate
of the symbiotic metabolism model (as compared to normal
metabolism) at various vessel densities were calculated; this allows for
an overall quantitative comparison between the two models.
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Figure 1. Symbiotic metabolism model (left), treatment naïve metabolism
model (right). Figure modified from [2].
Figure 3. Steady state solutions to the treatment naïve (non-adaptive) model applied to the vessels identified
from the histological stain of RCC cells as shown in Figure 2b. Observe the distinct gradients of oxygen,
glucose, pyruvate, and lactate around from the vessels.
The hypothesized symbiotic metabolic model qualitatively agrees
with histological stains of a tumour treated with Sunitinib, on the
basis of areas with lactate exporters (MCT4) present. This indicates
that the model is fairly accurate.
Further implementing the model, simulations over various vessel
densities consistently show that symbiotic metabolism results in
higher ATP production than normal metabolism. It is therefore viable
that this symbiotic adaptation allows for the continued survival and
growth of RCC through the recycling of lactate (allowing glucose to
diffuse farther). Lactate is normally not imported into cells, so lactate
importers must be newly expressed for symbiotic metabolism. As
such, inhibition of lactate importers could possibly be used to
decrease resistance.
Lastly, it was found from the vessel density simulations that the
symbiotic model allows for the greatest energy advantage at low
vessel densities. As such, anti-angiogenic treatment of RCC must aim
to reduce blood vessel density enough to harm the tumour, while
avoiding this adaptive metabolism from taking over too quickly.
RESULTS
Figure 7. Ratio of ATP production rate for symbiotic model vs the treatment
naïve model, for various vessel densities. Orange and green lines indicate
the vessel densities of the Sunitinib-treated (Fig 2b) and treatment naïve (Fig
2a) stains used in this study, respectively. Observe that the greatest energy
benefit from the symbiotic metabolism occurs at a very low vessel density.
Note that although the ATP production ratio of the Sunitinib-treated stain is
not much higher than the treatment naïve model, the adaptation did occur.
Figure 6. Average ATP production rate for various vessel densities, calculated separately for non-adaptive and
adaptive metabolism models. Densities were simulated using square matrices of various sizes as domains, with
a single blood vessel in the centre. As seen in the graph, adaptive metabolism always provides more energy.
This benefit is small at high (normal) vessel densities, and is greater at lower vessel densities.
Figure 4. Steady state solutions to the post-treatment (adaptive) model applied to the vessels identified from the
histological stain of RCC cells as shown in Figure 2b. Compared to Figure 3, observe that the glucose is more
widely distributed and lactate levels increase far from the blood vessels. This agrees with the model shown in
Figure 1, where lactate is exported in areas far from blood vessels to allow glucose consumption to be more
evenly distributed.
Figure 2 Immunohistochemistry stains of (a) treatment naïve and (b) sunitinib
treated RCC cells. Red indicates CD31 (blood vessels), green indicates MCT4
(lactate exporters), and blue indicates nuclei. Vessel densities for (a) and (b) are
5.1% and 0.3%, respectively. Figure from [1].
Sunitinib treated
stain (Fig 2b)
Figure 5. Lactate exporter (MCT4) levels as found from the histological stain (left) and as predicted by the
adaptive metabolic model results (right) displayed in Figure 4. White indicates the presence of MCT4.
Qualitatively, the two plots show similar regions, indicating that the metabolic model is fairly accurate.
Treatment naïve
stain (Fig 2a)
